CareDx Presents 50 Abstracts at ISHLT 2026, Highlighting Non-Invasive Transplant Monitoring
Event summary
- CareDx presented 50 abstracts, including 16 oral presentations, at the ISHLT 2026 Annual Meeting, showcasing data from 95 transplant centers.
- Key findings include early detection of rejection in heart and lung transplants using non-invasive molecular testing.
- The SHORE and ALAMO studies provided evidence supporting the clinical utility of AlloSure and AlloMap in post-transplant surveillance.
- CareDx introduced the MERIT trial, a randomized controlled study evaluating management strategies for heart transplant patients.
The big picture
CareDx's presentation at ISHLT 2026 underscores the growing importance of non-invasive molecular testing in transplant medicine. The company's focus on evidence generation aligns with the broader trend towards precision medicine, where data-driven diagnostics are increasingly integral to patient management. The strategic emphasis on heart and lung transplants positions CareDx to capture a significant share of the post-transplant surveillance market, potentially driving revenue growth and expanding its clinical impact.
What we're watching
- Clinical Validation
- Whether the SHORE and ALAMO study findings will translate into broader clinical adoption and reimbursement approvals.
- Trial Outcomes
- The pace at which the MERIT trial will provide actionable data on the efficacy of molecular testing-guided management strategies.
- Market Expansion
- How CareDx will leverage these data to expand its market share in non-invasive transplant monitoring.
Related topics